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Summary Despite the advances in chemotherapy for cancer patients, infectious
complications remain an important cause of mortality and morbidity. Surveillance data
report not only a shift in the aetiology of infections and resistance patterns in this
patient population, but also important differences between regions and countries. Viridans
streptococcal bacteraemias are common among cancer patients being second only to the
coagulase-negative staphylococci. However, in certain centres in Europe Gram-negative
bacilli have once again become the predominant infecting pathogens. The problems
associated with emerging resistance have been widely documented in the literature.
In some institutions methicillin-resistance among coagulase-negative staphylococci has
reached 75%, and in others the incidence of extended-spectrum beta-lactamase producing
Gram-negative bacilli has risen markedly. These shifts in antimicrobial susceptibility are
important in guiding the choice of agents for febrile neutropenia. Antibiotic use and
prophylaxis have both been associated with changes in susceptibility, and prescribing habits
may inﬂuence emerging resistance. In this context, the choice of empirical antibiotic
therapy and the use of prophylaxis should be driven by a sound understanding of local
circumstances.
© 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
reserved.
Introduction
Despite advances in antimicrobial therapy, infectious
complications remain an important cause of mortality and
morbidity among febrile neutropenic patients. Important
regional differences in the aetiology of infection exist.
Surveillance data from the International Antimicrobial
Therapy Group (IATG) of the European Organisation for
Research and Treatment of Cancer (EORTC) show a shift
in the aetiology of infection and in the patterns of
resistance (Figure 1). Before the mid-1980s Gram-negative
bacilli were the predominant pathogens associated with
bacteraemia. In trials undertaken during the late 1980s
there was a shift to Gram-positive cocci which became the
dominant isolates until the turn of the century when the
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Figure 1. Single agent bacteraemia in EORTC–IATG trials (1972–
2000) 1.
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Figure 2. Predominant pathogens reported in US cancer
patients (SCOPE) 1995–2000 2.
Gram-negative bacilli re-emerged, notably Pseudomonas
aeruginosa, Escherichia coli and the other enteric Gram-
negative bacilli. This shift may be partially explained by
a decrease in the use of ﬂuoroquinolone as prophylaxis.
A comparison of data from IATG–EORTC reported a
signiﬁcant decline in overall mortality (P = 0.001) and
mortality associated with single agent Gram-positive
bacterial infections (P = 0.009) between Trial V (1986) 3
and Trial XIV (2000) 4. However, mortality associated with
infections due to single species Gram-negative bacilli
over the same period did not change. This re-emergence
of Gram-negative bacilli has important implications for
managing these patients; though, these trends are not
found globally.
In the USA, data from the Surveillance and Con-
trol of Pathogens of Epidemiologic Importance (SCOPE)
Project reports Gram-positive bacteria as the predominant
pathogens in both neutropenic and non-neutropenic
patients 2. Between 1995 and 2000 these isolates have
signiﬁcantly increased (P = 0.001), with coagulase-negative
staphylococci (CoNS) and Staphylococcus aureus predom-
inating. In cancer patients without neutropenia, SCOPE
has reported an increase in enterococci during this time.
Importantly, among patients with severe neutropenia
viridans streptococci were the third most commonly
isolated pathogen (Figure 2), accounting for 1 in 10
isolates. In terms of Gram-negative bacilli, SCOPE data
reports E. coli, Klebsiella spp. and P. aeruginosa as the
most commonly isolated organisms. There were also high
levels of resistance to methicillin amongst CoNS (77%)
and S. aureus (29%), to vancomycin among Entero-
coccus faecium (VRE) (56%), to cephalosporins among
the Enterobacteraceae (42%) but relatively low levels
of cephalosporin (7%) and carbapenem-resistance (6%)
amongst isolates of P. aeruginosa. However, resistant
patterns differ between regions, countries and between
institutions, which is an important consideration in terms
of managing this patient group.
Epidemiology of infections in cancer
patients
In a review of the incidence of bacteraemia among
haematopoietic stem cell transplant recipients over a
7-year period, a shift in the aetiology of infection
Figure 3. Resistance rates of Streptococcus spp. in BMT
patients 1991–1997 5.
was noted, although the overall infection rate fell 5.
During the ﬁrst 5 years of this survey the Gram-positive
cocci predominated, although the ratio of Gram-positive
to Gram-negative bacteria declined from 2.7 to 1.3.
Viridans streptococci, primarily Streptococcus mitis and
Streptococcus sanguis, accounted for 49% of Gram-positive
bacteria, followed by CoNS (20%) and S. aureus (6%),
whilst E. coli and Klebsiella spp. were the most
commonly isolated bacteria accounting for over half of
the Gram-negative bacilli isolated. A signiﬁcant increase
in resistance to penicillin, ciproﬂoxacin and imipenem
among the streptococci was noted during this time
(Figure 3), and 40–45% of Enterobacter spp., Serratia spp.
and Citrobacter spp. were resistant to ceftazidime and
piperacillin, 50% of E. coli and Klebsiella spp. isolates
were resistant to piperacillin and 15% of P. aeruginosa
isolates were resistant to ceftazidime and tobramycin.
EORTC data show a similar increase in the incidence of
streptococcal infections, rising from 12% (1973–78) 6,7 to
47% (1998–2000) 4.
An earlier study also reported a predominance of
Gram-positive bacteraemias among Italian paediatric
cancer patients over a one-year period 8. Of these,
123 (64%) occurred in neutropenic and 68 (36%) in
non-neutropenic patients. Gram-positive cocci caused
45% (85/191) of the episodes, Gram-negative bacilli
41% (78/191), and fungi 9% (18/191). The remaining
5% (10/191) of episodes were poly-microbial infections. A
12-year survey in a single Italian tertiary centre reported
that single-species Gram-positive bacteraemia accounted
for 79/153 episodes (52%), single-species Gram-negative
bacteraemia for 64 (42%), polymicrobial bacteraemia for
5 (3%) and isolated fungaemia for 5 (3%) episodes,
respectively 9. CoNS, viridans streptococci and S. aureus
were the most commonly isolated Gram-positive bacteria
[26/84 (31%), 25/84 (30%) and 19/84 (23%), respectively]
and Klebsiella, Enterobacter, Serratia group, E. coli
and P. aeruginosa the most commonly isolated Gram-
negative bacilli [19/70 (27%), 15/70 (21%) and 14/70 (20%),
respectively]. These data all conﬁrm the importance of
viridans streptococci as a risk factor for patients with
febrile neutropenia. The intensity of chemotherapy was
an associated risk factor for infection in this patient
group. Data from IATG–EORTC Trials IX and XI show that
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Table 1
Sites of infection in cancer patients (September 2001 –
February 2002) 10








Pneumonia 93 (38) 99 (26)
Bloodstream 88 (35) 74 (20)
Urinary tract 27 (11) 85 (22)
Skin and soft tissue 17 (6) 65 (17)
Gastrointestinal 16 (6) 38 (10)
Other 12 (4) 17 (5)
Total 253 (100) 378 (100)
15% (129/836) of the evaluable patients developed a
secondary infection, of which half were attributable to
Gram-positive bacteria and 42% (54/129) were attributable
to a fungal infection 11. CoNS accounted for 44% (11/25) of
the Gram-positive isolates.
Analysis of data from Turkey over an 18-year period
shows a similar increase in single species Gram-positive
bacteraemia among cancer patients 12. In 2004, CoNS
accounted for ~70% of infections and enterococci for 13%.
Interestingly the incidence of S. aureus infections had
fallen from 47% (1991–94) to 9.6% in 2004. In single agent
Gram-negative infections, E. coli had fallen from 58% in
1994 to 30% in 2004, Enterobacter spp. from 27% to 8%,
whilst Klebsiella spp. and P. aeruginosa had increased from
7% to 23% and 11% to 23%, respectively. This shift in aeti-
ology towards the Gram-positives was associated with an
increase in the number of patients undergoing haematopoi-
etic stem cell transplantation at Hacettepe University
Hospital. A sub-analysis of all isolates from 2004 showed
that the Gram-negative bacilli were the dominant isolates
accounting for 52% (243/468) of all-cause infections,
whereas they accounted for only 41.5% of bacteraemias.
Among haematopoietic stem cell transplant recipients
and/or those with indwelling intravascular catheters,
the Gram-positive cocci were the dominant pathogens
accounting for 59% (135/229) during the same period.
New data presented at the 16th European Congress
of Clinical Microbiology and Infectious Diseases (ECCMID)
from MD Anderson Cancer Centre at Houston, Texas,
in the USA reported a rise in Gram-positive bacteria
causing bacteraemia among cancer patients from 73% of
1055 in 1998 to 82% of 1025 in 2004 13. Amongst Gram-
negative bacilli E. coli and P. aeruginosa accounted for
24% and 19%, respectively, and other Enterobacteriacae
and non-fermenting Gram-negative bacilli for 32% and 25%,
respectively. A sharp increase was noted in rates of
isolation of Stenotrophomonas maltophilia, i.e. 6% in 1994
vs 16% in 2004 (p < 0.01). Compared with the Gram-
positive infections reported by this group, a signiﬁcant
proportion of the Gram-negative bacteraemia were high-
grade (18% vs 39% in 1998, and 7% vs 44% in 2004;
P < 0.001).
A recent letter pointed out that focussing only on
monomicrobial nosocomial bacteraemia may be misleading
as this presents only part of the picture associated with
infections in cancer patients 10. This group reported that
these bacteraemias accounted for only 35% of infections
among patients with haematological malignancies and
20% of infections among patients with solid tumours
(Table 1). The National Cancer Institute has also
reported that the number of polymicrobial infections has
dramatically increased since the 1970s and accounts for
23–31% of documented bacterial infections, with ~80%
of these infections having a Gram-negative bacillary
component and ~33% being caused exclusively by multiple
Gram-negative bacilli.
Emerging resistance and problem
pathogens
Methicillin resistance among CoNS has reached an
incidence of 75% in some institutions 14. Some isolates
also have intermediate susceptibility to vancomycin,
and occasionally vancomycin-resistant coagulase-negative
staphylococci have been described 15. The emergence of
methicillin-resistance has been widely documented in the
literature. Methicillin-resistant S. aureus is associated
with signiﬁcant mortality and morbidity 16. However, an
unexpectedly high mortality rate (33.4%) related with
CoNS infections was reported in the SCOPE trial 2. The
same data indicated relatively lower mortality rates
associated with infections caused by methicillin-resistant
S. aureus (17.7%).
The increasing levels of resistance, particularly amongst
viridans streptococci, is also of concern in cancer patients.
Multi-drug resistance in this group of streptococci was ﬁrst
reported in 1996 17, and the frequency of isolation of viri-
dans streptococci from the blood of neutropenic patients
with cancer has signiﬁcantly increased over the course of
the last 10–20 years. Risk factors in this patient population
include severe neutropenia, oral mucositis, administration
of high-dose cytosine arabinoside, and antimicrobial
prophylaxis with either trimethoprim-sulfamethoxazole or
a ﬂuoroquinolone. Figure 3 illustrates the rise in penicillin
resistance between 1991–1997 in a single centre trial with
haematopoietic stem cell transplant recipients 9. Table 2
shows the rates of resistance to various antimicrobials
reported in three different studies conducted between
1995 and 2002. Similar trends have also been reported
in data from the USA 2,18. Recently, Han et al. 18 reported
28% (7/25) S. mitis strains isolated from cancer patients
to be resistant to penicillin (MIC > 4mg/mL). These strains
were also signiﬁcantly more resistant to ﬂuoroquinolones
and to 3 classes of antibiotics. Young and elderly patients
have higher levels of bacteraemia associated with S. mitis
and a signiﬁcant level of septic shock is caused by S. mitis
(P = 0.007) in these patients.
The incidence of extended-spectrum b-lactamases
(ESBLs) has increased in many institutions 19 and has also
been reported in the isolates from Hacettepe University
Hospital, where the incidence of ESBLs has reached ~50% in
patients with ventilator-associated pneumonia. Among
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Table 2
Percentage resistance of viridans Streptococci in patients
with cancer 1995–2002
Antibiotic 1995a 2000b 2002c
Penicillin 56 40 79
Cefotaxime 45 24 –
Ceftriaxone – 22 47
Ceftazidime 74 56 47
Cefepime – 34 58
Imipenem 30 7 –
Erythromycin 40 36 –
Rifampin 0 – –
Vancomycin 0 0 –
a Carratala (1995) 20; b Marron (2000) 21; c Bruckner (2002) 22.
cancer patients 31% of E. coli and 25% of Klebsiella spp.
were shown to be ESBL producers, and the incidence among
blood culture isolates was 36% and 29%, respectively 12.
Data from MYSTIC surveillance (1997–99) reported the
incidence of ESBLs in Europe to be 23.4%, 2.8% and 1.5%
and AmpC beta-lactamase producers to be 13.2%, 18.1%
and 12.5% among isolates from neutropenic patients over
the three years reported 23. A study of the incidence of
ESBL-producing K. pneumoniae among febrile neutropenic
paediatric patients conducted in Kuala Lumpur in 1996–97
reported that 51.6% of isolates were ESBL producers 24.
Infections associated with these isolates were associated
with a signiﬁcantly longer duration of hospitalisation
(21.9 versus 4.3 days, P = 0.003), and identiﬁed prior
cephalosporin use within the previous two weeks to
be a risk factor for colonisation with ESBL producers.
Sepsis-related mortality was also signiﬁcantly higher in
children infected with resistant strains (50.0% versus
13.3%, P = 0.002).
Siu and co-workers 25 reported data from 13 paediatric
patients who presented with 16 episodes of bacteraemia
between 1993 and 1997 from an oncology ward with
a high level of resistance among Gram-negative bacilli.
Intermediate susceptibility to cefotaxime was reported
for all isolates, and molecular characterisation identiﬁed
two K. pnuemoniae and three E. coli to be carrying both
SHV-5 and TEM-1 genes while the isolate of K. pneumoniae
carried both SHV-2 and SHV-5 genes. Although there are
a lot of data in the literature relating to the incidence
of ESBLs, there is a paucity of information among febrile
neutropenic patients. However the few publications cited
above suggest that these pathogens should be considered
when initiating treatment of cancer patients when there is




In response to the emerging resistance in Gram-negatives,
particularly E. coli, the use of ﬂuoroquinolone prophylaxis
has declined. Data from 14 centres participating in EORTC
XI and XIV shows a fall in the use of ﬂuoroquinolone
prophylaxis from 55% to 28% 26. The incidence of
ﬂuoroquinolone-resistant E. coli dropped from 38% to
20% between the two studies. However, the incidence of
Gram-negative bacteraemia increased from 6.2% (24/386)
to 9.6% (32/332) in patients receiving ﬂuoroquinolone
prophylaxis and 9.2% (35/386) to 14.5% (48/332) in patients
who had not received prophylaxis between the two trials.
A recent randomised controlled study of ﬂuoroquinolone
prophylaxis versus placebo among 760 neutropenic cancer
patients reported a lower rate of microbiologically deﬁned
infections (absolute difference in risk, – 17 percent;
95% conﬁdence interval [CI]: – 24% to – 10%; P < 0.001),
bacteraemias (difference in risk, – 16 percent; 95%CI:
– 22% to – 9%; P < 0.001), and single-species Gram-
negative bacillary bacteremias (difference in risk, – 7%;
95%CI: – 10% to– 2%; P < 0.01) in the levoﬂoxacin arm 27.
Gram-negative bacilli were isolated from 3% of patients
receiving the drug versus 1% of those receiving placebo.
Amongst the Gram-negative bacteraemias, 77% (10/13)
versus 17% (4.24) of isolates were resistant to levoﬂoxacin
in the treated and placebo groups, respectively, as
were 91% (31/34) and 64% (28/44) of Gram-positive
isolates. Methicillin-resistant CoNS was the most frequently
isolated Gram-positive species and all were resistant to
levoﬂoxacin.
A German study investigating the epidemiologic evo-
lution of ﬂuoroquinolone resistance of E. coli in a
haematology–oncology unit recommending ﬂuoroquinolone
prophylaxis during episodes of neutropenia reported
a dramatic decline in the levels of resistance after
withdrawing ﬂuoroquinolone prophylaxis, from 56% to 15%
(P = 0.002; Figure 4) 28. There was no signiﬁcant difference
in the incidence of fever per neutropenic episode during
the three study periods (7/1997–1/1998, 2/1998–7/1998
and 8/1998–1/1999), however during the period when
prophylaxis was withdrawn, more patients developed
bacteraemias (34%) than in the periods prior- and post-
study intervention (28% and 19%, respectively). More
polymicrobial infections were also reported in the period
with no prophylaxis, 8% versus 3% and 1%, respectively.
A recent meta-analysis of clinical trials comparing ﬂuo-
roquinolone prophylaxis with placebo (22 trials) or other
antibiotics (35 trials) was presented at the 16th ECCMID 29.
Figure 4. Quinolone-resistant E. coli bacteraemia in
haematology–oncology patients. Adapted from Kern et al.,
2005 28.
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Surveillance data were available for 28 of the studies.
When ﬂuoroquinolones were compared to placebo or no
intervention, there was a trend to colonisation with
resistant E. coli among those receiving a ﬂuoroquinolone
(RR 1.68, 95%CI: 0.71–4.0), however the rate of infection
did not increase signiﬁcantly. These authors concluded
that the reduction in mortality associated with the use
of ﬂuoroquinolones probably outweighs the risk of the
development of resistance.
Summary
Gram-negative bacilli have re-emerged as the dominant
pathogens in some European centres treating cancer
patients, whereas in the USA and elsewhere the Gram-
positive cocci still predominate. Changes in the aetiology
of infection among neutropenic patients and the increase
in b-lactam resistance make it imperative to give careful
consideration to the choice of drug for empirical therapy.
There is also evidence that bacteraemia due to viridans
streptococci, particularly among haematopoietic stem cell
transplant recipients, may be increasing and that this is
also associated with an increase in antibiotic resistance,
morbidity and mortality. This again has implications
for antimicrobial management. As for ﬂuoroquinolone
prophylaxis, this also increases the rate of resistance but
further studies are needed to quantify the beneﬁt or harm
of prophylaxis with these agents in this patient group.
References
1. Viscoli C. Management of infection in cancer patients.
studies of the EORTC International Antimicrobial Therapy
Group (IATG). Eur J Cancer 2002;38(Suppl 4):S82–7.
2. Wisplinghoff H, Seifert H, Wenzel RP, et al. Current trends
in the epidemiology of nosocomial bloodstream infections
in patients with hematological malignancies and solid
neoplasms in hospitals in the United States. Clin Infect
Dis 2003;36(9):1103–10.
3. European Organization for Research and Treatment
of Cancer (EORTC) International Antimicrobial Therapy
Cooperative Group and the National Cancer Institute
of Canada-Clinical Trials Group. Vancomycin added to
empirical combination antibiotic therapy for fever in
granulocytopenic cancer patients. J Infect Dis 1991;
163(5):951–8.
4. Cometta A, Kern WV, De Bock R, et al. Vancomycin
versus placebo for treating persistent fever in patients
with neutropenic cancer receiving piperacillin-tazobactam
monotherapy. Clin Infect Dis 2003;37(3):382–9.
5. Collin BA, Leather HL, Wingard JR, et al. Evolution,
incidence, and susceptibility of bacterial bloodstream
isolates from 519 bone marrow transplant patients. Clin
Infect Dis 2001;33(7):947–53.
6. EORTC International Antimicrobial Therapy Project Group.
Trimethoprim-sulfamethoxazole in the prevention of
infection in neutropenic patients. J Infect Dis 1984;
150(3):372–9.
7. International Antimicrobial Therapy Cooperative Group of
the European Organization for Research and Treatment of
Cancer. Reduction of fever and streptococcal bacteremia
in granulocytopenic patients with cancer. A trial of oral
penicillin V or placebo combined with peﬂoxacin. JAMA
1994;272(15):1183–9.
8. Viscoli C, Castagnola E, Giacchino M, et al. Bloodstream
infections in children with cancer: a multicentre
surveillance study of the Italian Association of Paediatric
Haematology and Oncology. Supportive Therapy Group-
Infectious Diseases Section. Eur J Cancer 1999;35(5):
770–4.
9. Castagnola E, Caviglia I, Pistorio A, et al. Bloodstream
infections and invasive mycoses in children undergoing
acute leukaemia treatment: a 13-year experience at
a single Italian institution. Eur J Cancer 2005;41(10):
1439–45.
10. Yadegarynia D, Tarrand J, Raad I, et al. Current spectrum
of bacterial infections in patients with cancer. Clin Infect
Dis 2003;37(8):1144–5.
11. Akova M, Paesmans M, Calandra T, et al. A European
organization for research and treatment of cancer-
international antimicrobial therapy group study of
secondary infections in febrile, neutropenic patients with
cancer. Clin Infect Dis 2005;40(2):239–45.
12. Calik N, Karaagaoglu E, Hascelik G, et al. Epidemiology
of bacterial infections and risk factors for mortality in
cancer patients. In: Program and Abstracts of Interscience
Conference of Antimicrobial Agents and Chemotherapy,
2005, Washington DC, USA. K-1529.
13. Safdar A, Rodriguez G, Balakrishnan M, et al. Changing
trends of bacteraemia in patients with cancer: analysis of
2080 quantative blood culture during 1998 and 2004. In:
Program and Abstracts of European Congress of Clinical
Microbiology and Infectious Diseases, 2006, Nice, France.
P681.
14. Wisplinghoff H, Bischoff T, Tallent SM, et al. Nosocomial
bloodstream infections in US hospitals: analysis of 24,179
cases from a prospective nationwide surveillance study.
Clin Infect Dis 2004;39(3):309–17.
15. Jones RN, Stilwell MG, Sader HS, et al. Spectrum and
potency of dalbavancin tested against 3322 Gram-positive
cocci isolated in the United States Surveillance Program
(2004). Diagn Microbiol Infect Dis 2006;54(2):149–53.
16. Schito GC. The importance of the development of
antibiotic resistance in Staphylococcus aureus. Clin
Microbiol Infect 2006;12(Suppl 1):3–8.
17. Doern GV, Ferraro MJ, Brueggemann AB, et al. Emergence
of high rates of antimicrobial resistance among viridans
group streptococci in the United States. Antimicrob Agents
Chemother 1996;40(4):891–4.
18. Han XY, Kamana M, Rolston KV. Viridans streptococci
isolated by culture from blood of cancer patients: clinical
and microbiologic analysis of 50 cases. J Clin Microbiol
2006;44(1):160–5.
19. Ramphal R, Ambrose PG, Pena C, et al. Extended-spectrum
beta-lactamases and clinical outcomes: current data.
Risk-factors for acquisition of extended-spectrum beta-
lactamase-producing Escherichia coli among hospitalised
patients. Clin Infect Dis 2006 Apr 15;42(Suppl 4):S164–72.
20. Carratala J, Alcaide F, Fernandez-Sevilla A, et al.
Bacteremia due to viridans streptococci that are highly
resistant to penicillin: increase among neutropenic
patients with cancer. Clin Infect Dis 1995;20(5):1169–73.
21. Marron A, Carratala J, Gonzalez-Barca E, et al.
Serious complications of bacteremia caused by Viridans
streptococci in neutropenic patients with cancer. Clin
Infect Dis 2000;31(5):1126–30.
22. Bruckner LB, Korones DN, Karnauchow T, et al. High
incidence of penicillin resistance among alpha-hemolytic
S8 M. Akova
streptococci isolated from the blood of children with
cancer. J Pediatr 2002;140(1):20–6.
23. Mendes C, Turner PJ. Unit differences in pathogen
occurrence arising from the MYSTIC program European
database (1997–2000). Diagn Microbiol Infect Dis 2001;
41(4):191–6.
24. Arifﬁn H, Navaratnam P, Mohamed M, et al. Ceftazidime-
resistant Klebsiella pneumoniae bloodstream infection in
children with febrile neutropenia. Int J Infect Dis 2000;
4(1):21–5.
25. Siu LK, Lu PL, Hsueh PR, et al. Bacteremia due to extended-
spectrum beta-lactamase-producing Escherichia coli and
Klebsiella pneumoniae in a pediatric oncology ward:
clinical features and identiﬁcation of different plasmids
carrying both SHV-5 and TEM-1 genes. J Clin Microbiol
1999;37(12):4020–7.
26. De Bock R, Cometta A, Kern WV, et al. Incidence of single
agent Gram-negative bacteremias (SAGNB) in netropenic
cancer patients (NCP) in EORTC-IATG trials of empiical
therapy for febrile neutropenia. In: Program and Abstracts
of 41st Interscience Conference on Antimicrobial Agents
and Chemotherapy, 2001, Chicago, USA. American Society
for Microbiology, Washington, DC, p. 455, Abstract L-733.
27. Bucaneve G, Micozzi A, Menichetti F, et al. Levoﬂoxacin
to prevent bacterial infection in patients with cancer and
neutropenia. N Engl J Med 2005;353(10):977–87.
28. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone
resistance of Escherichia coli at a cancer center:
epidemiologic evolution and effects of discontinuing
prophylactic ﬂuoroquinolone use in neutropenic patients
with leukemia. Eur J Clin Microbiol Infect Dis 2005;24(2):
111–8.
29. Gafter-Gvili A, Paul M, Fraser A, et al. Effect of quinolone
prophylaxis on resistance in afebrile neutropenic patients –
systematic review. In: Program and Abstracts of European
Congress of Clinical Microbiology and Infectious Diseases,
2006, Nice, France. P685.
